SignalCorporate
FDA warns of rare vision-loss side effect from GLP-1 drugs
FDA warning on rare vision-loss side effect from GLP-1 drugs signals regulatory risk.
Context
What happened: The FDA said a new warning about a rare side effect that can lead to permanent vision loss will be added to labeling for all GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro.
Key numbers: FDA analysis of more than 125 clinical trials found the condition in roughly 6 of every 100,000 patients on a GLP-1 for at least a year,
Why it matters: Novo Nordisk said the data do not establish cause and effect and it remains confident in the benefit-risk profile. Eli Lilly said the communication applies to all GLP-1 medicines and cites no findings specific to Lilly drugs.
Coverage: 3 outlets in 24h
What changed
The FDA said a new warning about a rare side effect that can lead to permanent vision loss will be added to labeling for all GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro.
Why it matters
Novo Nordisk said the data do not establish cause and effect and it remains confident in the benefit-risk profile. Eli Lilly said the communication applies to all GLP-1 medicines and cites no findings specific to Lilly drugs.